Why Hansa Biopharma’s ConfIdeS trial could reshape kidney transplant desensitization
Hansa Biopharma’s imlifidase faces a decisive FDA year as Phase 3 transplant data test whether desensitization can unlock donor access.
Hansa Biopharma’s imlifidase faces a decisive FDA year as Phase 3 transplant data test whether desensitization can unlock donor access.